摘要
目的探讨阿法骨化醇联合唑来膦酸的治疗方案对骨质疏松患者骨密度及OPG、BMP-2的影响。方法将80例骨质疏松患者随机分成联合组和单一治疗组。两组患者均接受常规基础治疗,单一治疗组患者在此基础上接受唑来膦酸治疗,联合治疗组患者接受阿法骨化醇联合唑来膦酸的治疗方案。于治疗前及治疗12个月后评估两组患者的腰椎正位(L_(2-4))骨密度、股骨颈骨密度、骨保护蛋白(OPG)水平、骨形态发生蛋白-2(BMP-2)水平及治疗效果。结果治疗后,两组患者的腰椎正位(L_(2-4))骨密度、股骨颈骨密度、OPG及BMP-2均较治疗前有所改变(P<0.01);联合治疗组患者的腰椎正位(L_(2-4))骨密度及股骨颈骨密度均高于单一治疗组患者(P<0.01);联合治疗组患者的OPG水平高于单一治疗组患者(P<0.01);联合治疗组患者的BMP-2水平高于单一治疗组患者(P<0.01);联合治疗组患者的总有效率(97.5%)高单一治疗组患者(82.5%)(P<0.01)。结论阿法骨化醇联合唑来膦酸在骨质疏松患者中的效果较好,可明显提高患者的骨密度,提高OPG水平,提升BMP-2水平,促进患者的恢复。
Objective To explore the effect of alfacalcidol combined with zoledronic acid on bone mineral density(BMD),osteoprotegerin(OPG),and bone morphogenetic protein-2(BMP-2)in patients with osteoporosis.Methods Eighty patients with osteoporosis were randomly divided into the combined treatment group and the single treatment group.Patients in both groups received conventional basic treatment.Patients in the single treatment group received zoledronic acid treatment,and patients in the combined treatment group received alfacalcidol combined with zoledronic acid treatment.BMD of the lumbar spine(L2-4)and the femoral neck,levels of OPG and BMP-2,and treatment effect were evaluated before and 12 months after treatment.Results After the treatment,BMD,OPG,and BMP-2 of the patients in both groups were different from those before the treatment(P<0.01).BMD of L2-4and the femoral neck were higher in the combined treatment group than in the single treatment group(P<0.01).The OPG level in the combined treatment group was higher than that in the single treatment group(P<0.01).The level of BMP-2 in the combined treatment group was higher than that in the single treatment group(P<0.01).Total effective rate was higher in the combined treatment group(97.5%)than that in the single treatment group(82.5%,P<0.01).Conclusion Alfacalcidol combined with zoledronic acid has a good effect in patients with osteoporosis,which can significantly improve BMD and the levels of OPG and BMP-2 and promote the recovery of the patients.
作者
胡玲
邹艺
尹晓玲
漆莉莹
HU Ling.;ZOU Yi;YIN Xiaoling;QI Liying(Department of Endocrinology,the Third Affiliated Hospital of Nanchang University,Nanchang 330008,China)
出处
《中国骨质疏松杂志》
CAS
CSCD
北大核心
2019年第1期93-96,共4页
Chinese Journal of Osteoporosis
关键词
阿法骨化醇
唑来膦酸
骨质疏松
骨密度
alfacalcidol
zoledronic acid
osteoporosis
bone mineral density
